

Jonathan Thomas, Ph.D., J.D.

Chairman, Independent Citizens Oversight Committee California Institute for Regenerative Medicine

# California Institute for Regenerative Medicine (CIRM)

DISCOVERY
TRANSLATIONAL
CLINICAL
EDUCATION
INFRASTRUCTURE

- Created by the people of California to accelerate stem cell treatments to patients with unmet medical needs
- We act with a sense of urgency commensurate with that mission
- Our team of professionals actively partners with academia and industry to fast-track the development of today's most promising technologies
- With \$3 billion in funding and 300 active programs, CIRM is the world's largest institution dedicated to helping people by developing cell therapies




# **Our Mission**

Accelerating stem cell treatments to patients with unmet medical needs.



# 668 Awards Since Inception Totaling \$2 Billion



#### **CIRM Impact: Infrastructure**

- 12 Major Facilities statewide
- \$271 M CIRM Investment
- \$844 M Leverage
- \$200 M tax revenue
- **25,000 jobs**







### **CIRM Impact: Growing the Field**

- Research Leadership Awards
- New Faculty Awards
- Training Awards
- Bridges Awards
- Creativity Awards






### **CIRM Impact: Portfolio**

\$1.3 billion invested in disease specific research including 15 clinical

trials





#### **CIRM Impact: Clinical Trials**

- HIV/AIDS (3)
- Solid Tumors (2)
- Heart Failure
- Leukemia
- Sickle Cell Anemia
- Spinal Cord Injury
- Type 1 Diabetes
- Macular Degeneration
- Retinitis Pigmentosa
- Malignant Melanoma
- Chronic Granulomatous Disease
- Glioblastoma



#### **Funding Runway**

Current levels sufficient to last approximately 5 years



- \$2 billion awarded or spent
- \$775 million uncommitted
- \$190-200 million in new awards per year
- Estimated \$20 million in award reductions annually
- Projected NET commitment rate of \$170 million per year




#### What is CIRM 2.0

- A radical overhaul of the way the Institute does business
- Introduces faster, more efficient systems
- Places added emphasis on:
  - √ Speed
  - ✓ Partnerships
  - ✓ Patients



### **CIRM 2.0 Purpose**





#### **Features of CIRM 2.0**

DISCOVERY
TRANSLATIONAL
CLINICAL
EDUCATION
INFRASTRUCTURE

- Faster process to produce a better product
- True partnership
- Real patient participation
- Open to a variety of therapeutics (cells, biologics, small molecules)
- Opportunities for California and Non-California organizations
- Ready when you are
- Highly competitive



## The Strategic Planning Process

### Where are we now?

- Evaluate environment
- Confront brutal facts
- Confirm mission

## Where do we want to go?

- Brainstorm options
- Benchmark
- Create a unique vision

### How do we get there?

- Determine strategy
- Establish milestones
- Document the plan



#### **Strategic Plan Implementation**

MISSION/VISION

#### STRATEGIC THEME

#### **SPECIFIC ACTIONS**

#### **PUSH**

Operational Excellence

- Fully Operationalize CIRM 2.0
- Construct Translation and Accelerating Centers
- · Coordinate and Focus Programs

Accelerate stem cell treatments to patients with unmet medical needs

#### **PULL**

**Engage Demand** 

- Launch the CIRM Exchange
- Public / Private Partnerships for Commercialization



- Organize an Army of Stakeholders
- Drive Regulatory Reform



#### **Financial Outlook**

MISSION/VISION

#### STRATEGIC THEME

#### **SPECIFIC ACTIONS**

Accelerate stem cell treatments to patients with unmet medical needs







Program	2016	2017	2018	2019	2020	Total
Education	10	10	10	10	10	50
Discovery	15	50	50	35	30	180
Translation	25	40	45	35	30	175
Clinical	100	85	75	75	65	400
Infrastructure	15	15	20	20	15	85
Totals	165	200	200	175	150	890



### **CIRM Strategic Goals**

MISSION/VISION

STRATEGIC THEME

**SPECIFIC ACTIONS** 

Accelerate stem cell treatments to patients with unmet medical needs

PUSH
Operational
Excellence

PULL Engage Demand

LEVEL Lower Hurdles

#### **INTENDED OUTCOMES**

50 new clinical trials

20 unique diseases in clinical trials

5 pediatric and 10 orphan indications in trial

Increase progression events to 33%

Reduce preclinical time by 50%

Drive implementation of new FDA paradigm

Partner >50% of unpartnered clinical projects



